Business
Perimeter Medical Imaging AI Announces Initiation of Additional Clinical Trial Site at Baptist MD Anderson Cancer Center in Jacksonville, FL
Perimeter Medical Imaging AI Announces Initiation of Additional Clinical Trial Site at Baptist MD...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n \n \n \n Perimeter Medical Imaging AI Announces Initiation of Additional Clinical Trial Site at Baptist MD Anderson Cancer Center in Jacksonville, FL\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Pivotal clinical trial underway to determine the impact of Perimeter B-Series OCT with ImgAssist AI on positive margin rates during breast conservation surgery\n \n \n \n \n \n TORONTO\n \n and\n \n DALLAS\n \n \n ,\n \n \n May 2, 2023\n \n \n /CNW/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) – Perimeter Medical Imaging AI, Inc. (\"Perimeter\" or the \"Company\") – a commercial-stage medical technology company – announced the initiation of an additional clinical trial site at Baptist MD Anderson Cancer Center in\n \n Jacksonville, FL\n \n under the direction of\n \n Laila Samiian\n \n , MD, FACS.\n \n \n \n \n \n \n \n \n \n \n Laila Samiian\n \n , MD, FACS, Director, Breast Program at Baptist MD Anderson Cancer Center, stated, \"We are excited to become the newest active site with three investigators anticipated to participate in this clinical study to assess if the Perimeter B-Series with artificial intelligence demonstrates an improvement over the current standard of care. Combining optical coherence tomography with deep learning algorithms could assist us, as surgeons, to better identify regions of interest supporting 'real-time' decisions on margin status in the OR – potentially setting a new standard for specimen imaging technology during breast conservation surgery.\"\n \n \n \n Jeremy Sobotta\n \n , Perimeter's Chief Executive Officer stated, \"Our ongoing pivotal clinical trial evaluating our breakthrough-device-designated Perimeter B-Series OCT technology with proprietary, next-gen 'ImgAssist' artificial intelligence continues to advance. All initially planned sites have been activated, and we recently received FDA approval to expand the number of institutions to further support patient enrollment. We are excited to initiate Baptist MD Anderson Cance...